NCT05567562CompletedPhase 2
Anti-Platelets in Chronic Obstructive Pulmonary Disease
Dual Anti-platelet Therapy in Chronic Obstructive Pulmonary Disease Study
Source: ClinicalTrials.gov · Last updated 14 May 2026
Brief summary (registry, in English)
This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs measured on a contrast CT scan) compared to placebo.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 3 Oct 2022
- Start date
- 27 Mar 2024
- Primary completion date
- 28 Feb 2025
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- COPD
- NCT number
- NCT05567562
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 15
- From 27 Mar 2024 to the primary completion date, 28 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Regular use of aspirin, clopidogrel or another antiplatelet medication;
- Daily use of oral steroids, theophylline, roflumilast, or loop diuretics;
- Use of a biologic medication with regular injections;
- IV drug use within the last year;
- Exacerbation of respiratory symptoms within the previous 6 weeks, such as that requiring hospitalization, oral prednisone or antibiotics to control symptoms, or longer and not yet returned to baseline; and
Other illness
- Allergy to aspirin, clopidogrel, albuterol or iodine/IV contrast;
- History of intracranial hemorrhage, severe GI bleed or other life-threatening bleed;
- History of organ transplant or autoimmune disease on systemic therapy (rheumatoid arthritis, lupus);
- Other current lung disease (interstitial lung disease, idiopathic pulmonary fibrosis, asthma);
- History of lung surgery to remove part of the lung;
- Treatment for cancer (systemic therapy or surgical/radiation within the thorax) in the last 12 months;
- Known diagnosis of pulmonary hypertension;
- Known systolic heart failure (RV or LV EF \< 40%);
- Chest, abdominal or eye surgery, or a heart attack or stroke, within the last 3 months.
Lab values
- Platelet count \< 150,000/dL or self-report of a bleeding disorder;
- Acute or chronic renal insufficiency (estimated glomerular filtration rate \[GFR\] \<60 mL/min/1.73 m2 or self-report). GFR will be calculated using the CKD-EPI equation;
Other
- BMI \> 35;
- Use of blood thinner (e.g. warfarin, lovenox or novel oral anti-coagulants);
- Continuous use of supplemental oxygen at home;
- Regular use of an NSAID;
- Known bullae or advanced destructive emphysema in more than 1/3 of the lungs;
- Current or planned pregnancy in the next year;
- Regular marijuana smoking;
Who the study is looking for
- COPD (FEV1/FVC \< 0.7, FVC \>= LLN), GOLD Stage I/II/III (FEV1 \>= 40%)
- Current or former smoker of at least 10 pack years
- Normal lung function (FEV1/FVC \>= 0.7, FEV1 and FVC \>= LLN)
- Current or former smoker of at least 10 pack years
Age in the registry: 50 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.